Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629173 | 0.91 | MAP3K12 (0.40) | MAP3K12PIK3CAKMT2AMTORHRH4 | |
| SCHEMBL9607456 | 0.91 | MAP3K12 (0.40) | MAP3K12PIK3CAKMT2AMTORHRH4 | |
| SCHEMBL9604992 | 0.84 | HRH3 (0.43) | MAP3K12PIK3CAKMT2AMTORLMNA | |
| SCHEMBL628524 | 0.84 | MAP3K12 (0.36) | MAP3K12CYP1A2CYP2D6MAPTPIK3CA | |
| SCHEMBL622689 | 0.84 | MAP3K12 (0.36) | MAP3K12CYP1A2CYP2D6MAPTPIK3CA | |
| SCHEMBL628366 | 0.80 | HRH4 (0.40) | MAP3K12PIK3CAMTORHRH4PIK3R1 | |
| SCHEMBL17527913 | 0.80 | MAP3K12 (0.34) | MAP3K12CYP1A2CYP2D6MAPTPIK3CA | |
| SCHEMBL26604079 | 0.80 | KMT2A (0.55) | MAP3K12CYP1A2CYP2D6MAPTPIK3CA | |
| SCHEMBL26604101 | 0.80 | KMT2A (0.55) | MAP3K12CYP1A2CYP2D6MAPTPIK3CA | |
| SCHEMBL629658 | 0.78 | HPGD (0.50) | MAP3K12MAPTPIK3CAKMT2AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419432-B9 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2419432-B9 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2419432-B1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2419432-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120998-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | MAP3K12 85/4885CYP1A2 3261/4885CYP2D6 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.